Vilon: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 10 sources cited
Overview
Vilon (Lys-Glu) is the shortest bioregulator peptide in the Khavinson family — a dipeptide designed to support immune function and thymic activity. Despite its minimal size (just two amino acids), research suggests it can modulate gene expression in immune cells. It is used as a thymic bioregulator in Russian anti-aging and immunological protocols.
Mechanism of Action
Vilon's dipeptide sequence (lysine-glutamic acid) is proposed to interact with DNA in the promoter regions of genes involved in T-cell development and immune regulation. Research by Khavinson's group suggests that even dipeptides can serve as epigenetic modulators, interacting with histone proteins and DNA to influence chromatin accessibility and gene transcription. In cultured human and rat thymus cells, Vilon and a related dipeptide raised a marker of T-lymphocyte differentiation (CD5), and Vilon boosted mouse thymocyte proliferation in vitro. It activated expression of the IL-2 gene, a cytokine necessary for T-cell proliferation, in mouse spleen cells in vitro; an effect on IL-7 has not been reported. The extremely small size is the basis for claims of oral bioavailability and blood-brain barrier penetration; modeling suggests di- and tripeptides can use intestinal peptide transporters, but neither has been measured for Vilon.
Vilon Benefits: What the Research Shows
- Khavinson et al. showed that the Lys-Glu dipeptide can interact with DNA and modulate gene expression in lymphoid tissue in cell culture studies
- A Russian clinical study in elderly patients with type 1 diabetes reported that adding vilon to standard therapy normalized levels of active T-lymphocytes, B-lymphocytes and IgA and lowered T-helper and NK cell counts (Advances in Gerontology, 2007)
- Research on dipeptide bioregulators shows they can cross cell membranes and enter the nucleus to interact with chromatin
- A study in rats exposed to low-dose radiation found that vilon partly prevented the accelerated aging of the thymus and spleen (Advances in Gerontology, 2002)
- The concept of ultra-short peptide bioregulation has been published in over 100 papers from the St. Petersburg institute
Vilon Dosage
- Oral: 1–2 capsules (10–20 mg) daily for 10–30 days
- Injectable: 10 mcg subcutaneously every other day for 10–20 days
- Repeat courses every 3–6 months
- Take on an empty stomach
- Often combined with thymogen and thymosin alpha-1 for comprehensive immune bioregulation
- Can be used as part of a seasonal immune support program
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Vilon Side Effects & Safety
Known Side Effects
- No side effects are described in the available literature, but the human studies are few, small and were not designed to assess safety
- Dipeptide structure is assumed to mean low immunogenicity; this has not been tested
- No adverse immune reactions documented
- Tolerability has not been systematically reported; published clinical use is limited to small Russian studies in elderly patients
Safety Profile
Vilon is one of the simplest bioregulator peptides, consisting of just two naturally occurring amino acids. Its safety has not been established in controlled human studies: the published evidence is a mouse lifespan study that noted no unfavourable effects and a few small Russian clinical reports that did not systematically record adverse events. Its metabolism and clearance in humans have not been studied. Western validation data is limited. No contraindications are established, though caution is advised in autoimmune conditions as with all immunomodulatory agents.
What to Expect
Bioregulator effects are gradual and subtle. No dramatic acute effects expected. Over 10–30 day courses, immune function may gradually normalize at the cellular level. Published human reports are limited to small studies in elderly patients. Repeat courses over months to years may produce cumulative improvements in immune resilience. Some users report fewer infections and improved general vitality after multiple courses.
Common Stacks
Thymogen
Thymogen (Glu-Trp) provides complementary thymic bioregulation through a different dipeptide sequence, broadening the scope of immune gene modulation
Thymosin Alpha-1
Tα1 provides pharmaceutical-grade immune modulation while vilon supports baseline thymic gene expression — different scales of immune intervention
Storage & Handling
Store capsules at room temperature (15–25°C), protected from moisture. Shelf life: 2–3 years. Injectable form: store at 2–8°C; reconstituted solution at 2–8°C for up to 14 days.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997.
- Khavinson VK, Anisimov VN, Zavarzina NY, et al. Effect of vilon on biological age and lifespan in mice. Bull Exp Biol Med. 2000.
- Sevostianova NN, Linkova NS, Polyakova VO, et al. Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells. Bull Exp Biol Med. 2013.
- Kazakova TB, Barabanova SV, Khavinson VKh, et al. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. Bull Exp Biol Med. 2002.
- Khavinson VKh, Rybakina EG, Malinin VV, et al. Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. Bull Exp Biol Med. 2002.
- Kuznik BI, Isakova NV, Kliuchereva NN, et al. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus. Adv Gerontol. 2007.
- Kniaz'kin IV, Poliakova VO. The effect of vilon on the thymus and spleen in a radiation model of premature aging. Adv Gerontol. 2002.
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004.
- Khavinson VK, Linkova NS, Ashapkin VV, et al. KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging. Adv Gerontol. 2023.
- Khavinson V, Linkova N, Kozhevnikova E, et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022.
Related Peptides
Track Vilon in Your Protocol
Log your Vilon doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free